Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Venmax Drugs & Pharmaceuticals EBITDA Margin % Related Terms
Venmax Drugs & Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Venmax Drugs & Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Venmax Drugs & Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Venmax Drugs & Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Venmax Drugs & Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Venmax Drugs & Pharmaceuticals (BOM:531015) has a EBITDA Margin % of 2.67% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Venmax Drugs & Pharmaceuticals and its competitors. According to the industry distribution chart, Venmax Drugs & Pharmaceuticals ranks #688 out of 960 companies in the Drug Manufacturers industry, placing it in the top 71.7%.
Is Venmax Drugs & Pharmaceuticals' EBITDA Margin % too high?
Venmax Drugs & Pharmaceuticals' current EBITDA Margin % is 2.67%. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Venmax Drugs & Pharmaceuticals' value of 2.67% is 78.7% below this industry median. Based on the distribution chart, Venmax Drugs & Pharmaceuticals ranks #688 out of 960 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Venmax Drugs & Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Venmax Drugs & Pharmaceuticals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Venmax Drugs & Pharmaceuticals ranks #688 out of 960 companies for EBITDA Margin %. This places Venmax Drugs & Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 12.52. Venmax Drugs & Pharmaceuticals' value of 2.67% is 78.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venmax Drugs & Pharmaceuticals's current EBITDA Margin % of 2.67% is 78.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Venmax Drugs & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venmax Drugs & Pharmaceuticals's current EBITDA Margin % is 2.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Venmax Drugs & Pharmaceuticals stock overvalued right now?
Venmax Drugs & Pharmaceuticals (BOM:531015) has a current EBITDA Margin % of 2.67%. The current EBITDA Margin % is 2.67% and 78.7% below the Drug Manufacturers industry median of 12.52. Venmax Drugs & Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Venmax Drugs & Pharmaceuticals (BOM:531015), the current EBITDA Margin % is 2.67% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Venmax Drugs & Pharmaceuticals Business Description
Venmax Drugs & Pharmaceuticals Ltd is engaged in the manufacturing and sale of bulk drugs. The company is engaged in the business of IT & ITES services.
33GF Score
Get the complete analysis for BOM:531015
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531015 has been successfully added to your 
